Melissa Przyborowski Olekson1, Renea A Faulknor1, Henry C Hsia2, Ann Marie Schmidt3, François Berthiaume1. 1. Department of Biomedical Engineering, Rutgers University , Piscataway, New Jersey. 2. Department of Surgery, Robert Wood Johnson Medical School, Rutgers University , New Brunswick, New Jersey. 3. Departments of Medicine, Pharmacology, and Pathology, New York University Medical Center , New York.
Abstract
Objective: In diabetes, hyperglycemia causes the accumulation of advanced glycation end products (AGEs) that trigger reactive oxygen species (ROS) generation through binding the receptor for AGEs (RAGE). Because exogenous growth factors have had little success in enhancing chronic wound healing, we investigated whether hyperglycemia-induced AGEs interfere with cellular responses to extracellular signals. We used stromal cell-derived factor-1 (SDF-1), an angiogenic chemokine also known to promote stem cell recruitment in skin wounds. Approach: Human leukemia-60 (HL-60) cells and mouse peripheral blood mononuclear cells (PBMCs), which express the SDF-1 receptor CXCR-4, were incubated for 24 h in medium supplemented with 25 mM d-glucose. Soluble RAGE (sRAGE) was used to block RAGE activation. Response to SDF-1 was measured in cellular migration and ROS assays. A diabetic murine excisional wound model measured SDF-1 liposome and sRAGE activity in vivo. Results: Hyperglycemia led to significant accumulation of AGEs, decreased SDF-1-directed migration, and elevated baseline ROS levels; it suppressed the ROS spike normally triggered by SDF-1. sRAGE decreased the ROS baseline and restored both the SDF-1-mediated spike and cell migration. Topically applied sRAGE alone promoted healing and enhanced the effect of exogenous SDF-1 on diabetic murine wounds. Innovation: While there is interest in using growth factors to improve wound healing, this strategy is largely ineffective in diabetic wounds. We show that sRAGE may restore signaling, thus potentiating the effect of exogenously applied growth factors. Conclusion: Blocking RAGE with sRAGE restores SDF-1-mediated cellular responses in hyperglycemic environments and may potentiate the effectiveness of SDF-1 applied in vivo.
Objective: In diabetes, hyperglycemia causes the accumulation of advanced glycation end products (AGEs) that trigger reactive oxygen species (ROS) generation through binding the receptor for AGEs (RAGE). Because exogenous growth factors have had little success in enhancing chronic wound healing, we investigated whether hyperglycemia-induced AGEs interfere with cellular responses to extracellular signals. We used stromal cell-derived factor-1 (SDF-1), an angiogenic chemokine also known to promote stem cell recruitment in skin wounds. Approach: Humanleukemia-60 (HL-60) cells and mouse peripheral blood mononuclear cells (PBMCs), which express the SDF-1 receptorCXCR-4, were incubated for 24 h in medium supplemented with 25 mM d-glucose. Soluble RAGE (sRAGE) was used to block RAGE activation. Response to SDF-1 was measured in cellular migration and ROS assays. A diabeticmurine excisional wound model measured SDF-1 liposome and sRAGE activity in vivo. Results:Hyperglycemia led to significant accumulation of AGEs, decreased SDF-1-directed migration, and elevated baseline ROS levels; it suppressed the ROS spike normally triggered by SDF-1. sRAGE decreased the ROS baseline and restored both the SDF-1-mediated spike and cell migration. Topically applied sRAGE alone promoted healing and enhanced the effect of exogenous SDF-1 on diabeticmurine wounds. Innovation: While there is interest in using growth factors to improve wound healing, this strategy is largely ineffective in diabetic wounds. We show that sRAGE may restore signaling, thus potentiating the effect of exogenously applied growth factors. Conclusion: Blocking RAGE with sRAGE restores SDF-1-mediated cellular responses in hyperglycemic environments and may potentiate the effectiveness of SDF-1 applied in vivo.
Authors: Margaret A Fonder; Gerald S Lazarus; David A Cowan; Barbara Aronson-Cook; Angela R Kohli; Adam J Mamelak Journal: J Am Acad Dermatol Date: 2008-02 Impact factor: 11.527
Authors: M T Goova; J Li; T Kislinger; W Qu; Y Lu; L G Bucciarelli; S Nowygrod; B M Wolf; X Caliste; S F Yan; D M Stern; A M Schmidt Journal: Am J Pathol Date: 2001-08 Impact factor: 4.307
Authors: Michael Morcos; Ahmed A R Sayed; Angelika Bierhaus; Benito Yard; Rüdiger Waldherr; Wolfgang Merz; Ingrid Kloeting; Erwin Schleicher; Stefani Mentz; Randa F Abd el Baki; Hans Tritschler; Michael Kasper; Vedat Schwenger; Andreas Hamann; Klaus A Dugi; Anne-Marie Schmidt; David Stern; Reinhard Ziegler; Hans U Haering; Martin Andrassy; Fokko van der Woude; Peter P Nawroth Journal: Diabetes Date: 2002-12 Impact factor: 9.461
Authors: Fatouma Touré; Günter Fritz; Qing Li; Vivek Rai; Gurdip Daffu; Yu Shan Zou; Rosa Rosario; Ravichandran Ramasamy; Arthur S Alberts; Shi Fang Yan; Ann Marie Schmidt Journal: Circ Res Date: 2012-04-17 Impact factor: 17.367
Authors: Katherine A Gallagher; Zhao-Jun Liu; Min Xiao; Haiying Chen; Lee J Goldstein; Donald G Buerk; April Nedeau; Stephen R Thom; Omaida C Velazquez Journal: J Clin Invest Date: 2007-05 Impact factor: 14.808
Authors: Raphael Clynes; Bernhard Moser; Shi Fang Yan; Ravichandran Ramasamy; Kevan Herold; Ann Marie Schmidt Journal: Curr Mol Med Date: 2007-12 Impact factor: 2.222